Pharmaceutical Business review

Nastech and Amylin sign diabetes nasal spray deal

Preclinical studies of the formulation have been completed in preparation for initiating studies to determine feasibility in human subjects.

Under the terms of the agreement, Nastech will receive milestone payments and royalties on product sales. If feasibility is successful and the program moves forward, milestone payments could reach up to $89 million in total, based on specific development, regulatory, and commercialization goals.

Amylin and Nastech will jointly develop the nasal spray formulation utilizing Nastech’s proprietary nasal delivery technology, and Amylin will reimburse Nastech for any development activities performed by Nastech under the agreement.

Amylin has overall responsibility for the development program, including clinical, non-clinical and regulatory activities, while Nastech’s efforts will focus on drug delivery and chemistry, manufacturing and controls activities. If a supply agreement is reached between the companies, Nastech may supply commercial product to Amylin and its Exenatide collaboration partner, Eli Lilly.